☆ 4.6 Article

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Economics

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA

Prajakta P. Masurkar et al.

Summary: This study evaluated the cost effectiveness of using CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) with letrozole in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. The study found that compared to letrozole alone, the cost effectiveness ratio of combining abemaciclib and letrozole was $457,538 per QALY gained.

PHARMACOECONOMICS (2023)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi et al.

Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis

Kun Tian et al.

Summary: This study evaluated the cost-effectiveness of first-line treatments for patients with recurrent or metastatic nasopharyngeal carcinoma from the Chinese payers' perspective. The results showed that toripalimab plus GP chemotherapy was more cost-effective compared to GP chemotherapy alone, while camrelizumab plus GP chemotherapy was not cost-effective. In the pairwise comparison between the two immunotherapy-related groups, toripalimab plus GP chemotherapy was more cost-effective.

ORAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Breast Cancer, Version 3.2022

William J. Gradishar et al.

Summary: This article discusses the complex therapeutic options for patients with noninvasive or invasive breast cancer, as well as the recommendations provided by the NCCN Clinical Practice Guidelines for Breast Cancer. It focuses on the overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Meeting Abstract Oncology

MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)

M. P. Goetz et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trial

B. Xu et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4

Binghe Xu et al.

Summary: The PALOMA-4 study demonstrates the efficacy and safety of first-line palbociclib plus letrozole in postmenopausal Asian women with ER+/HER2- ABC. No new safety concerns were identified for the combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer

Hope S. Rugo et al.

Summary: This study analyzed clinical practice data of MBC patients in the US using the Flatiron Health Analytic Database and found that first-line treatment with palbociclib plus an aromatase inhibitor significantly improved overall survival and progression-free survival in HR+/HER2- MBC patients.

NPJ BREAST CANCER (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis

Xiaoting Huang et al.

Summary: The study found that adding RIB to endocrine therapy as a first-line treatment for premenopausal women with HR-positive, HER2-negative ABC is unlikely to provide a reasonable return for the money spent in the United States. However, in China, the value-based price of RIB established in this study could prove helpful during drug price negotiations for eligible patients.

CLINICAL BREAST CANCER (2021)

Add to Collection

Review Oncology

Current trends in the treatment of HR+/HER2+breast cancer

Charlene Kay et al.

Summary: Treatment for HR+/HER2+ patients has been debated due to varying tumor behaviors within this subtype. Recent research suggests a combination of hormone and targeted anti-HER2 approaches may provide long-term disease control for some patients. New therapies targeting HER2 and HR+ cancers are being evaluated in combination for potential treatment strategies.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR plus )/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)

Add to Collection

Article Oncology

Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China

XiaoMin Wan et al.

BREAST (2019)

Add to Collection

Article Oncology

Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer

Bingnan Zhang et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Article Oncology

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

H. S. Rugo et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Article Oncology

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Stephen Johnston et al.

NPJ BREAST CANCER (2019)

Add to Collection

Article Oncology

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

G. N. Hortobagyi et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Health Care Sciences & Services

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain

Elena Galve-Calvo et al.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)

Add to Collection

Article Oncology

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

J. Raphael et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer

H. Mamiya et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Letter Oncology

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

K. Matter-Walstra et al.

BREAST CANCER RESEARCH AND TREATMENT (2017)

Add to Collection

Article Medicine, General & Internal

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

T. Bell et al.

CURRENT MEDICAL RESEARCH AND OPINION (2016)

Add to Collection

Article Medicine, General & Internal

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

G. N. Hortobagyi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Richard S. Finn et al.

BREAST CANCER RESEARCH (2016)

Add to Collection

Article Oncology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn et al.

LANCET ONCOLOGY (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

The history and future of targeting cyclin-dependent kinases in cancer therapy

Uzma Asghar et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Medicine, General & Internal

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

Nicholas C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010

Gonghuan Yang et al.

LANCET (2013)

Add to Collection

Article Health Care Sciences & Services

Improved curve fits to summary survival data: application to economic evaluation of health technologies

Martin W. Hoyle et al.

BMC MEDICAL RESEARCH METHODOLOGY (2011)

Add to Collection

Article Multidisciplinary Sciences

Molecular portraits of human breast tumours

CM Perou et al.

NATURE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.